title: Targeting mammalian target of rapamycin (mTOR) for health and diseases.
abstract: The macrolide rapamycin is used clinically to treat graft rejection and restenosis. Mammalian target of rapamycin (mTOR) is a central controller of cellular and organism growth that integrates nutrient and hormonal signals, and regulates diverse cellular processes. New studies have linked mTOR to several human diseases including cancer, diabetes, obesity, cardiovascular diseases and neurological disorders. Recent data have also revealed that mTOR is involved in the regulation of lifespan and in age-related diseases. These findings demonstrate the importance of growth control in the pathology of major diseases and overall human health, and underscore the therapeutic potential of the mTOR pathway.
authors.affiliation: Department of Pharmacology and Cancer Institute of New Jersey (CINJ) Robert Wood Johnson Medical School, 675 Hoes Lane, Piscataway, NJ 08854 USA.
authors.forename: Chi Kwan
authors.initials: CK
authors.lastname: Tsang
authors.forename: Haiyan
authors.initials: H
authors.lastname: Qi
authors.forename: Leroy F
authors.initials: LF
authors.lastname: Liu
authors.forename: X F Steven
authors.initials: XF
authors.lastname: Zheng
mesh_terms: D000375:Aging / Q000187:drug effects; D000818:Animals; D002908:Chronic Disease / Q000188:drug therapy; D016503:Drug Delivery Systems; D015195:Drug Design; D006801:Humans; D007166:Immunosuppressive Agents / Q000494:pharmacology*; D008017:Life Expectancy; D011494:Protein Kinases / Q000187:drug effects / Q000502:physiology*; D020123:Sirolimus / Q000819:agonists* / Q000494:pharmacology*; D058570:TOR Serine-Threonine Kinases
chemical_list: D007166:Immunosuppressive Agents; D011494:Protein Kinases; C546842:MTOR protein, human; D058570:TOR Serine-Threonine Kinases; D020123:Sirolimus